Who owns GAIN THERAPEUTICS INC?
- Ticker: GANX
- CUSIP Number: 36269b105
Tip: Access positions for across all investors
Analyze quarterly positions in Gain Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Gain Therapeutics stock
Who bought or sold GAIN THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Jones Financial Companies, L.L | 677k | $1.2M | 0% | Sep 2025 |
|
| DME Capital Management | 566k | $1.0M | 0% | Sep 2025 |
|
| Vanguard Group | 534k | $946k | 0% | Sep 2025 |
|
| Citadel Advisors | 384k | $679k | 137% | Sep 2025 |
|
| Geode Capital Management | 344k | $609k | 18% | Sep 2025 |
|
| Cambridge Investment Research Advisors | 319k | $564k | 78% | Sep 2025 |
|
| Marshall Wace | 175k | $310k | -37% | Sep 2025 |
|
| UBS Group | 141k | $249k | 331% | Sep 2025 |
|
| Renaissance Technologies | 126k | $223k | 34% | Sep 2025 |
|
| BlackRock | 116k | $206k | 3% | Sep 2025 |
|
| State Street Corporation | 91k | $161k | 28% | Sep 2025 |
|
| Northern Trust | 88k | $157k | -12% | Sep 2025 |
|
| Susquehanna International | 80k | $142k | -32% | Sep 2025 |
|
| Morgan Stanley | 77k | $138k | 100% | Jun 2025 |
|
| Jane Street | 73k | $128k | 100% | Sep 2025 |
|
| XTX Topco | 54k | $96k | 100% | Sep 2025 |
|
| Virtu Financial | 54k | $96k | 127% | Sep 2025 |
|
| Kovitz Investment Group Partners | 48k | $84k | 0% | Sep 2025 |
|
| Squarepoint Ops | 39k | $68k | 100% | Sep 2025 |
|
| Springbok Capital Management | 36k | $63k | 0% | Sep 2025 |
|
| Benedict Financial Advisors | 35k | $62k | 56% | Sep 2025 |
|
| Bridgeway Capital Management | 30k | $53k | 0% | Sep 2025 |
|
| Two Sigma Securities | 27k | $48k | 100% | Sep 2025 |
|
| Jpmorgan Chase & Co | 26k | $47k | 100% | Sep 2025 |
|
| Hrt Financial | 20k | $34k | 100% | Sep 2025 |
|
| Group One Trading | 17k | $30k | 162% | Sep 2025 |
|
| Wealth Enhancement Advisory Services | 16k | $31k | 100% | Sep 2025 |
|
| Sandhill Capital Partners | 15k | $27k | 0% | Sep 2025 |
|
| Kestra Advisory Services | 12k | $21k | 100% | Sep 2025 |
|
| HighTower Advisors | 12k | $21k | 100% | Sep 2025 |
|
| Armis Advisers | 11k | $20k | 0% | Sep 2025 |
|
| Goss Wealth Management | 11k | $19k | 0% | Sep 2025 |
|
| Creekmur Asset Management | 4.4k | $7.9k | 0% | Sep 2025 |
|
| MAI Wealth Advisors | 4.4k | $7.8k | 0% | Sep 2025 |
|
| SRS Capital Advisors | 3.3k | $5.8k | 30% | Sep 2025 |
|
| Wells Fargo & Company | 2.7k | $4.7k | 0% | Sep 2025 |
|
| Tower Research Capital | 2.1k | $3.7k | 118% | Sep 2025 |
|
Who sold out of Gain Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Gotham Asset Management | Jun 2025 | 246k | $5.4M |
| Dauntless Investment Group | Jun 2025 | 46k | $83k |
| GSA Capital Partners | Jun 2025 | 13k | $23k |
| Simplex Trading | Jun 2025 | 5.7k | $10k |
| Raymond James Financial | Jun 2025 | 2.3k | $4.1k |